QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ABCL

QT54AbCellera Biologics Inc.
NASDAQ·Healthcare·Biotechnology·Canada
Latest market price
5.53
+0.09+1.65%
OverviewShort InterestFilings
ABCLQT54AbCellera Biologics Inc.·NASDAQ
OverviewShort InterestFilings
5.53+1.65%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.48
Insider Own-
Shs Outstand305.38M
Perf Week4.93%
Market Cap1.66BForward P/E-EPS next Y-0.64Insider Trans0.09%Shs Float-Perf Month36.54%
Enterprise Value1.72BPEG-EPS next Q-0.17Inst Own-Short Float-Perf Quarter56.66%
Income-145026252.00P/S20.97EPS this Y-22.92%Inst Trans-Short Ratio-Perf Half Y59.83%
Sales79.21MP/B1.76EPS next Y-9.23%ROA-11.01%Short Interest-Perf YTD61.70%
Book/sh3.07P/C-EPS next 5Y-ROE-14.86%52W High6.79 -18.56%Perf Year77.24%
Cash/sh1.65P/FCF-EPS past 3/5Y-ROIC-13.84%52W Low2.75 101.09%Perf 3Y-
Dividend Est.-EV/EBITDA-10.94Sales past 3/5Y-46.32% -20.28%Gross Margin79.07%Volatility5.30% 6.67%Perf 5Y-
Dividend TTM-EV/Sales21.77EPS Y/Y TTM12.73%Oper. Margin-267.61%ATR (14)0.48Perf 10Y-
Dividend Ex-Date-Quick Ratio13.89Sales Y/Y TTM172.41%Profit Margin-181.75%RSI (14)55.03Recom2.18
Dividend Gr. 3/5Y-Current Ratio14.05EPS Q/Q6.67%SMA20-0.28%Beta2.69Target Price7.50
Payout0.00%Debt/Eq0.15Sales Q/Q100.00%SMA5015.93%Rel Volume0.91Prev Close5.44
Employees596LT Debt/Eq0.14EarningsAug 06SMA20029.86%Avg Volume7.44MPrice5.53
IPO DateDec 11, 2020Option/ShortYes / YesEPS/Sales Surpr.36.36% 60.00%Net Debt/EBITDA-0.40Volume6,784,898Change1.65%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedStifel Nicolaus$7.00 → $8.00
May-05-26InitiatedCantor FitzgeraldOverweight$7.00
Nov-07-25DowngradeLeerink PartnersOutperform → Market Perform
Nov-05-24ReiteratedBMO CapitalOutperform$5.00
Aug-23-24ReiteratedKeyBancOverweight$7.00 → $5.00
Aug-20-24DowngradeBenchmarkBuy → Hold
May-08-24ReiteratedKeybancOverweight$7.00
Feb-22-24UpgradeBenchmarkHold → Buy
Jan-06-23ReiteratedLeerink Partners$18
Dec-15-22ReiteratedGoldman SachsBuy$30
Latest News
Jun-17-26
Jun-17-2612:54PM
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera CollaborationBenzinga
07:11AM
Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific AntibodiesBenzinga
06:33AM
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its CashSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue797529
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A17290
Gross Profit634629
Selling, General and Administrative Excl. Other737785
Research and Development191187167
Other Operating Expense11-192
Operating Income-213-217-315
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-24-40-14
Net Income Before Taxes-174-178-200
Income Taxes-31-31-38
Consolidated Net Income-144-146-163
Net Income From Continuing Operations-144-146-163
Net Income-144-146-163
EPS (Recurring)-0.48-0.49-0.55
EPS (Basic, Before Extraordinaries)-0.48-0.49-0.55
EPS (Diluted)-0.48-0.49-0.55
EBITDA-158-149-204
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio21.2113.63—
Gross Margin79.7561.33100.00
Operating Margin-269.62-289.33-1,086.21
Net Margin-182.28-194.67-562.07
Shares Outstanding303299294
Market Capitalization1,6761,023—
Operating Lease Expense
———
Insider Trading Volume
$6.13$5.51$4.89$4.27$3.65● Close Price0.00K214.17K428.35K642.52K856.70KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Montalbano John S.DirectorMay 14 '26Buy4.7720,00095,400241,000May 18 12:00 AM
Thermopylae Holdings Ltd.10% OwnerFeb 27 '26Buy3.4438,000130,72056,134,097Mar 02 12:00 AM
Booth AndrewChief Financial OfficerFeb 27 '26Buy3.4242,600145,692195,600Feb 27 12:00 AM
Thermopylae Holdings Ltd.10% OwnerFeb 26 '26Buy3.27177,457580,28456,096,097Feb 27 12:00 AM
Montalbano John S.DirectorNov 26 '25Buy3.5750,000178,460221,000Nov 26 12:00 AM
Thermopylae Holdings Ltd.10% OwnerMar 11 '25Buy2.16343,631742,24356,143,640Mar 11 12:00 AM
Montalbano John S.DirectorMar 10 '25Buy2.3025,00057,500171,000Mar 10 12:00 AM
Montalbano John S.DirectorMar 06 '25Buy2.3460,000140,568146,000Mar 07 12:00 AM
Hansen Carl L. G.Chief Executive OfficerNov 25 '24Option Exercise2.70112,250303,0768,260,223Nov 26 12:00 AM
Hansen Carl L. G.Chief Executive OfficerSep 20 '24Option Exercise2.70112,250303,0768,316,348Sep 24 12:00 AM
Thermopylae Holdings Ltd.10% OwnerAug 29 '24Buy2.61283,516739,97756,086,009Aug 29 12:00 AM
Lecault VeroniqueChief Operating OfficerJun 21 '24Option Exercise0.19166,66831,3343,829,771Jun 24 12:00 AM
Hansen Carl L. G.Chief Executive OfficerMay 31 '24Option Exercise2.70112,250303,0768,372,473Jun 03 12:00 AM
Hansen Carl L. G.Chief Executive OfficerFeb 26 '24Option Exercise2.70112,250303,0768,428,598Feb 27 12:00 AM
Hansen Carl L. G.Chief Executive OfficerNov 23 '23Option Exercise2.70112,250303,0766,389,191Nov 27 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR